Group One Trading
CRVS icon

Group One Trading’s Corvus Pharmaceuticals CRVS Stock Holding History

Group One Trading’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$89.6K Sell
6,000
-6,200
-51% -$86K ﹤0.01% 4949
2026
Q1 		$178K Sell
12,200
-21,100
-63% -$337K ﹤0.01% 4209
2025
Q4 		$256K Buy
33,300
+11,700
+54% +$92.3K ﹤0.01% 4145
2025
Q3 		$159K Buy
21,600
+6,900
+47% +$35.3K ﹤0.01% 4916
2025
Q2 		$58.8K Sell
14,700
-52,100
-78% -$190K ﹤0.01% 5441
2025
Q1 		$212K Sell
66,800
-99,200
-60% -$467K ﹤0.01% 3961
2024
Q4 		$888K Buy
166,000
+163,000
+5,433% +$1.22M ﹤0.01% 2677
2024
Q3 		$15.8K Buy
3,000
+800
+36% +$2.87K ﹤0.01% 5365
2024
Q2 		$4K Sell
2,200
-1,700
-44% -$3.17K ﹤0.01% 6038
2024
Q1 		$6.94K Sell
3,900
-400
-9% -$835 ﹤0.01% 6048
2023
Q4 		$7.57K Sell
4,300
-1,400
-25% -$2.05K ﹤0.01% 6337
2023
Q3 		$8.32K Buy
5,700
+3,100
+119% +$6.56K ﹤0.01% 6453
2023
Q2 		$5.95K Buy
+2,600
New +$5.4K ﹤0.01% 6647
2022
Q3 		– Sell
-13,300
Closed -$13K – 7627
2022
Q2 		$13K Sell
13,300
-4,700
-26% -$5.76K ﹤0.01% 6599
2022
Q1 		$30K Sell
18,000
-3,600
-17% -$6.59K ﹤0.01% 6469
2021
Q4 		$52K Sell
21,600
-7,600
-26% -$29.5K ﹤0.01% 6304
2021
Q3 		$141K Buy
29,200
+25,000
+595% +$74K ﹤0.01% 5539
2021
Q2 		$11K Buy
4,200
+3,200
+320% +$8.81K ﹤0.01% 7474
2021
Q1 		$3K Sell
1,000
-1,700
-63% -$6.14K ﹤0.01% 7330
2020
Q4 		$10K Buy
2,700
+100
+4% +$403 ﹤0.01% 5778
2020
Q3 		$10K Buy
+2,600
New +$10.4K ﹤0.01% 5420

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Group One Trading's CRVS Position: Q2 2026 in Review

Group One Trading opened a new position in Corvus Pharmaceuticals (CRVS) in Q2 2026: 48,292 shares worth $721K. The stake represents ﹤0.01% of the portfolio and ranks #3170 among its holdings. This is a return to the name: Group One Trading previously reported a position in CRVS as recently as Q4 2025.

Group One Trading first reported a position in CRVS in Q3 2020 and has held it in 16 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Group One Trading held 48,292 shares of Corvus Pharmaceuticals worth $721K as of Q2 2026.
  • Corvus Pharmaceuticals was a new Group One Trading position in Q2 2026.
  • Corvus Pharmaceuticals made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #3170 holding.
  • Group One Trading first reported a position in Corvus Pharmaceuticals in Q3 2020 and has held it in 16 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.